Presentation is loading. Please wait.

Presentation is loading. Please wait.

SANOFI-SYNTHELABOARIXTRA ® 1 ARIXTRA ® (fondaparinux sodium) in the prevention of venous thromboembolism after hip replacement surgery KA Bauer, BI Eriksson,

Similar presentations


Presentation on theme: "SANOFI-SYNTHELABOARIXTRA ® 1 ARIXTRA ® (fondaparinux sodium) in the prevention of venous thromboembolism after hip replacement surgery KA Bauer, BI Eriksson,"— Presentation transcript:

1 SANOFI-SYNTHELABOARIXTRA ® 1 ARIXTRA ® (fondaparinux sodium) in the prevention of venous thromboembolism after hip replacement surgery KA Bauer, BI Eriksson, MR Lassen, and AGG Turpie on behalf of the Steering Committees of the Pentasaccharide Orthopaedic Prophylaxis Studies

2 SANOFI-SYNTHELABOARIXTRA2 EPHESUS AND PENTATHLON 2000: OBJECTIVE AND DESIGN  To compare the efficacy and safety of o.d. s.c. injections of Arixtra ® 2.5 mg with enoxaparin in preventing venous thromboembolism (VTE) in patients undergoing elective hip replacement surgery.  Two multicenter, randomized, double-blind, two-parallel-group comparative trials in 4584 patients.

3 SANOFI-SYNTHELABOARIXTRA3 EPHESUS AND PENTATHLON 2000: DESIGN Arixtra ® 2.5 mg o.d. Enoxaparin 40 mg o.d. or 30 mg b.i.d. start pre-op or post-op start 6 ± 2 hrs post-op Venogram Day 5–11 Follow up Day 42 ± 7 Treatment 7 ± 2 Days R

4 SANOFI-SYNTHELABOARIXTRA ® 4 EPHESUS AND PENTATHLON 2000: ENDPOINTS  Primary efficacy: VTE up to day 11  deep-vein thrombosis (DVT) detected by mandatory bilateral venography, or  documented symptomatic DVT, or  pulmonary embolism.  Primary safety: Major bleeding.

5 SANOFI-SYNTHELABOARIXTRA5 EPHESUS AND PENTATHLON 2000: EFFICACY RESULTS  3411 (74.4%) patients included in the primary efficacy analysis  Compared with enoxaparin Arixtra ® also reduced the incidence of:  any DVT from 8.6% to 4.7%  any proximal DVT from 1.9% to 1.2%  distal-only DVT from 7.0% to 3.8% 0 2 4 6 10 Arixtra ® n = 1,695 Enoxaparin n = 1,716 p =1. 4x10 -5 8.8% n=151 5.0% n=85 VTE (%) 8 1. Turpie et al. Arch Intern Med 2002 RR 43.0% 1

6 SANOFI-SYNTHELABOARIXTRA ® 6 EPHESUS AND PENTATHLON 2000: SAFETY RESULTS Arixtra ® N=2,268 n (%) Enoxaparin N=2,262 n (%) Fatal bleeding00 Bleeding in critical organ00 Bleeding leading to reoperation7 (0.3)5 (0.2) Bleeding with a bleeding index*  2 60 (2.6)37 (1.6) *The bleeding index was calculated as follows: [number of units of packed red blood cells or whole blood transfused] + [(pre-bleeding) - (post-bleeding) hemoglobin (g/dl) values].

7 SANOFI-SYNTHELABOARIXTRA ® 7 EPHESUS AND PENTATHLON 2000: CONCLUSION In patients undergoing elective hip replacement surgery, Arixtra ® provided a major benefit over enoxaparin in preventing VTE without increasing the risk of clinically relevant bleeding


Download ppt "SANOFI-SYNTHELABOARIXTRA ® 1 ARIXTRA ® (fondaparinux sodium) in the prevention of venous thromboembolism after hip replacement surgery KA Bauer, BI Eriksson,"

Similar presentations


Ads by Google